Proactive Investors - Run By Investors For Investors

Genprex to present at the Singular Research Summer Solstice conference

The biopharmaceutical company is making great strides toward developing its non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex
A researcher in a lab
Investors can hear Genprex CEO Rodney Varner talk about Oncoprox, which is in Phase 2 clinical trials

Genprex Inc (NASDAQ:GNPX), a clinical-stage gene-therapy company, announced Thursday that CEO Rodney Varner will present at the Singular Research Summer Solstice 2018 in New York City.

Varner will be presenting Thursday at 10.40 am ET at the high-profile conference in the small- and micro-cap space.

The Austin, Texas-based biopharmaceutical company is making great strides toward developing its non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex.

Varner earlier told Proactive Investors that Oncoprox is in Phase 2 of clinical trials, and next steps are to meet with the FDA about best pathways forward to an approval.

The company recently went public, raising $6.4mln. Varner said the biopharma will use the funds to continue clinical trials and expand and/or accelerate development programs into additional drug combinations.

Investors will be tuning into the conference for more details about progress on Oncoprox.

Investor excitement about the lung cancer-fighting, gene-therapy drug sent Genprex stock more than 1% higher to US$7.39 on Thursday's premarket action.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

View full GNPX profile View Profile

Genprex, Inc. Timeline

Related Articles

scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Oncoprex
October 18 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use